**FOI Ref: 6382**

**Category(ies): Clinical - Drugs**

**Subject: Usage of Intra-Vitreal Injections or Implants**

**Date Received: 11/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2022:
* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Fluocinolone acetonide
* Ranibizumab
 | * Aflibercept – 792
* Bevacizumab – 0
* Brolucizumab  - 0
* Dexamethasone  - 3
* Fluocinolone acetonide – 3
* Ranibizumab – 1040
 |
| 1. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.
 |

|  |
| --- |
| Number of Injections/Implants: Jan to Apr 2022 |
|   | **Eye Conditions** |
| **Treatment** | Wet Age-Related Macular Degeneration wAMD | Diabetic Macular Degeneration DMO | Retinal Vein Occulusion RVO |
| Aflibercept  | 412  | 201 |  179 |
| Bevacizumab  | 0 |  0  |  0 |
| Brolucizumab   |  0 |  0  |  0  |
| Dexamethasone   |  0  |  0  |  3  |
| Fluocinolone acetonide |  0  |  2 |  1 |
| Ranibizumab  |  579  |  232  |  229  |

 |